KYNB Stock Forecast: Kyntra Bio, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Kyntra Bio, Inc. is $24. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 41 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Kyntra Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Issuance (94): The share count has been shrinking and the company is not leaning on new borrowing.
Momentum (12): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
KYNB stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on KYNB, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Of the 20 most recent actions, 0 moved their price target up and 7 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 17 Nov 2026 | HC Wainwright & Co. | Maintains | Buy | $43 → $18 |
| 17 Nov 2026 | Lake Street | Maintains | Buy | $41 → $8.00 |
| 17 Nov 2026 | Oppenheimer | Maintains | Outperform | $35 → $30 |
| 13 Oct 2026 | Maxim Group | Initiates | Buy | $35 |
| 17 Sept 2026 | Lake Street | Initiates | Buy | $41 |
| 1 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | $43 |
| 7 July 2026 | Oppenheimer | Initiates | Outperform | $35 |
| 9 June 2026 | Rodman & Renshaw | Initiates | Buy | — |
| 24 Sept 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 Aug 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 13 May 2025 | HC Wainwright & Co. | Reiterates | Buy | $10 |
| 18 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | $10 |
| 20 Feb 2025 | HC Wainwright & Co. | Reiterates | Buy | $10 |
| 8 Aug 2023 | B of A Securities | Downgrade | Underperform | $4.00 → $2.00 |
| 27 June 2023 | Goldman Sachs | Maintains | Sell | $16 → $2.00 |
| 27 June 2023 | Raymond James | Downgrade | Market Perform | — |
| 26 June 2023 | B of A Securities | Downgrade | Neutral | $29 → $4.00 |
| 26 June 2023 | Raymond James | Downgrade | Market Perform | — |
| 26 June 2023 | Stifel | Downgrade | Hold | $28 → $11 |
| 26 June 2023 | William Blair | Downgrade | Market Perform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for KYNB.
This page is one stock. Monday covers all of them.
KYNB appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
KYNB vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Kyntra Bio, Inc. returned −81.2% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
KYNB analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 1.4×
- Price / book
- —
- EV / EBITDA
- —
Cheaper than 58% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- —
- Return on assets
- −38.9%
- Dividend yield
- —
Higher than 11% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Kyntra Bio, Inc. has a market value of $7.4M.
Revenue in the twelve months to 30 June 2026: $4.6M. The latest quarter shrank 209.3% year on year.
Net income over the same four quarters: $183.2M, a 3967.8% net margin.
Diluted earnings per share, trailing twelve months: $45.30.
Free cash flow in the twelve months to 30 June 2026: −$38.1M.
Kyntra Bio, Inc. employs 34 people — $136K of revenue per employee.
Data provided by Twelve Data
KYNB and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at KYNB’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Kyntra Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about KYNB
What is the KYNB stock price forecast for 2026-2027?
The median 12-month analyst price target for Kyntra Bio, Inc. is $24, with estimates ranging from $8 to $35. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is KYNB stock a buy right now?
Of the 5 analysts covering Kyntra Bio, Inc., 4 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Kyntra Bio, Inc. 41 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank KYNB?
As at 21 Nov 2026, Kyntra Bio, Inc. ranks 41 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Issuance (94 of 100).
Will KYNB stock go up?
No one can know that. What the data says: the median 12-month target from 5 analysts is $24, and Ticker Nerd's factor model ranks Kyntra Bio, Inc. 41 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the KYNB stock forecast for 2030?
No analyst covering Kyntra Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KYNB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $35 over the next 12 months.
How has KYNB stock performed over the past year?
Kyntra Bio, Inc. returned -81.2% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Kyntra Bio, Inc. do?
Kyntra Bio, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapies for serious unmet medical needs. Kyntra Bio’s current pipeline centers on oncology and anemia, including FG-3246, an antibody-drug conjugate targeting CD46 for metastatic castration-resistant prostate cancer and other cancers, as well as roxadustat, a small-molecule HIF-PH inhibitor being developed for anemia-related indications.
About Kyntra Bio, Inc.
Kyntra Bio, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapies for serious unmet medical needs. Kyntra Bio’s current pipeline centers on oncology and anemia, including FG-3246, an antibody-drug conjugate targeting CD46 for metastatic castration-resistant prostate cancer and other cancers, as well as roxadustat, a small-molecule HIF-PH inhibitor being developed for anemia-related indications. The company also works in fibrotic disease biology through its research on hypoxia-inducible factor and connective tissue growth factor pathways. Headquartered in San Francisco, California, Kyntra Bio serves the broader life sciences market by advancing treatments intended for patients with cancer, blood disorders, and other severe diseases.
CEO Mr. Thane Wettig · 34 employees · United States · https://www.kyntrabio.com